Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers

Molecular profiling is becoming increasingly relevant in the management of patients with advanced cancer; to identify targetable aberrations and prognostic markers to enable a precision medicine strategy. Eligible patients were those diagnosed with advanced biliary tract cancer (BTC) including intra...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical medicine 2020-09, Vol.9 (9), p.2854
Main Authors: Lamarca, Angela, Kapacee, Zainul, Breeze, Michael, Bell, Christopher, Belcher, Dean, Staiger, Helen, Taylor, Claire, McNamara, Mairéad G, Hubner, Richard A, Valle, Juan W
Format: Article
Language:English
Subjects:
Biopsy
Cancer therapies
Chemotherapy
Cholangiocarcinoma
Clinical medicine
DNA damage
Gallbladder cancer
Medical prognosis
Mutation
Patients
Precision medicine
Survival analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Molecular profiling is becoming increasingly relevant in the management of patients with advanced cancer; to identify targetable aberrations and prognostic markers to enable a precision medicine strategy. Eligible patients were those diagnosed with advanced biliary tract cancer (BTC) including intrahepatic (iCCA) and extrahepatic cholangiocarcinoma (eCCA), gallbladder cancer (GBC), and ampullary carcinoma (Amp) who underwent molecular profiling between April 2017 and June 2020 based on analysis of either tumour samples (FoundationOne CDx /Oncomine platforms) or ctDNA (FoundationOne Liquid platform (Foundation Medicine, Cambridge, MA, USA)). Baseline patient characteristics and molecular profiling outcomes were extracted. The primary aim was to describe sample failure rate. Secondary aims included description of reason for sample failure, summary of findings derived from molecular profiling, and assessment of concordance between paired tissue and ctDNA samples. A total of 149 samples from 104 individual patients diagnosed with advanced BTC were identified and eligible for this analysis: 68.2% iCCA, 100% advanced stage; 94.2% received palliative therapy. The rate of sample failure was 26.8% for tissue and 15.4% for ctDNA; -value 0.220, predominantly due to insufficient (defined as
ISSN:2077-0383
2077-0383
DOI:10.3390/jcm9092854